Adverse reactions to canagliflozin could not be reliably verified without access to medical claims data and thus were not reported
Adverse reactions to canagliflozin could not be reliably verified without access to medical claims data and thus were not reported. type 1 diabetes, providers have prescribed these agents for off-label use in this patient population. Glycemic variability may be problematic in patients with type 1 diabetes; therefore, Rabbit Polyclonal to OR6Q1 adding an SGLT2 inhibitor…